Cullinan Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 15.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 967.25M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp...